531739 Stock Overview
Engages in manufacturing and selling of bulk drugs, intermediates, and biotech products. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Gennex Laboratories Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹18.96 |
| 52 Week High | ₹29.00 |
| 52 Week Low | ₹13.25 |
| Beta | 0.93 |
| 11 Month Change | -13.23% |
| 3 Month Change | 3.95% |
| 1 Year Change | 18.06% |
| 33 Year Change | 168.18% |
| 5 Year Change | 565.26% |
| Change since IPO | 1,480.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| 531739 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | -0.6% | -0.5% | -1.2% |
| 1Y | 18.1% | 41.6% | 25.5% |
Return vs Industry: 531739 underperformed the Indian Pharmaceuticals industry which returned 40.5% over the past year.
Return vs Market: 531739 underperformed the Indian Market which returned 27.3% over the past year.
Price Volatility
| 531739 volatility | |
|---|---|
| 531739 Average Weekly Movement | 8.7% |
| Pharmaceuticals Industry Average Movement | 6.0% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in IN Market | 9.1% |
| 10% least volatile stocks in IN Market | 4.0% |
Stable Share Price: 531739's share price has been volatile over the past 3 months compared to the Indian market.
Volatility Over Time: 531739's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 129 | Arihant Baid | www.gennexlab.com |
Gennex Laboratories Limited engages in manufacturing and selling of bulk drugs, intermediates, and biotech products. The company offers Guaifenesin, Methocarbamol, Fexifenadine Hcl, Phenazopyridine Hcl, Fluconazole, Melitracen Hcl, Mephenesin, Chlorphenesin, Sertraline Hcl, and Allopurinol. It operates in India, Colombia, Egypt, Germany, Iran, Peru, Saudi Arabia, Spain, Thailand, and Vietnam.
Gennex Laboratories Limited Fundamentals Summary
| 531739 fundamental statistics | |
|---|---|
| Market cap | ₹4.31b |
| Earnings (TTM) | ₹149.84m |
| Revenue (TTM) | ₹985.48m |
28.8x
P/E Ratio4.4x
P/S RatioIs 531739 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 531739 income statement (TTM) | |
|---|---|
| Revenue | ₹985.48m |
| Cost of Revenue | ₹616.37m |
| Gross Profit | ₹369.11m |
| Other Expenses | ₹219.27m |
| Earnings | ₹149.84m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.66 |
| Gross Margin | 37.45% |
| Net Profit Margin | 15.20% |
| Debt/Equity Ratio | 10.7% |
How did 531739 perform over the long term?
See historical performance and comparison